Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2026)

Amneal Pharmaceuticals has reported EBT Margin for 10 years, with the latest figure at 8.92% in Q2 2026.

• On a quarterly basis, EBT Margin rose 178.0% year-over-year to 8.92% in Q2 2026; TTM through Jun 2026 was 6.45%, a 332.0% increase from a year earlier, with the FY2025 full-year figure at 4.61%, up 658.0% from the prior year.
• EBT Margin was 8.92% for Q2 2026 at Amneal Pharmaceuticals, down from 11.1% in the prior quarter.
• The five-year high for EBT Margin was 11.1% in Q1 2026, with the low at 41.61% in Q2 2022.
• Average EBT Margin over 5 years is 1.16%, with a median of 1.3% recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 4812 bps in 2022, then jumped 4656 bps in 2023.
• Over 5 years, EBT Margin stood at 1.26% in 2022, then sank by 978 bps to 13.53% in 2023, then surged by 84 bps to 2.1% in 2024, then soared by 423 bps to 6.78% in 2025, then jumped by 31 bps to 8.92% in 2026.
• The last three EBT Margin figures came in at 8.92% (Q2 2026), 11.1% (Q1 2026), and 6.78% (Q4 2025), per Business Quant data.